Two more Korean firms secure OTC derivatives licences

South Korean firms Dongbu Securities and Seoul Securities have received over-the-counter derivatives licences, the highest level of dealing licences in Korea, enabling them to issue equity-linked derivatives, securities and warrants.

Meanwhile, US banks Citi and Morgan Stanley, along with Korean firms Hanwha Securities and SK Securities, missed out on licences in this most recent round of applications, which were submitted in June (see: Citi, Hanwha withdraw applications for Korean OTC licences).

Citi declined to comment, but a source close to the bank said it was forced to withdraw its application because the Financial Supervisory Service, the executive arm of Korean regulator the Financial Supervisory Commission (FSC), "changed the requirements" and that the bank is likely to re-apply at some undisclosed point. A Morgan Stanley spokesperson said the bank doesn't comment on licence applications. The FSC also declined to comment for this article.

An Asia Risk source says the FSC has told firms that the next round of applications can be submitted in September. It is understood that Deutsche Bank and UBS are making preparations to apply for licences, although spokesmen for both banks declined to comment.

Macquarie Securities Korea in March became the first – and remains the only – foreign dealer to obtain a full OTC licence.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here